Cencora Inc. Q1 2026 Earnings Recap

COR Q1 2026 February 4, 2026

Get alerts when COR reports next quarter

Cencora, Inc. reported a strong start to fiscal 2026, achieving adjusted operating income growth of 12% and adjusted diluted EPS growth of 9% driven by strategic investments and acquisitions.

Earnings Per Share Beat

$4.08 vs $4.05 est.

+0.7% surprise

Revenue Miss

85932020000 vs 86058910000 est.

-0.1% surprise

Market Reaction

1-Day +6.72%

5-Day +10.83%

30-Day +8.88%

See COR alongside your other holdings

Add to your portfolio — free

Key Takeaways

Completed acquisition of OneOncology, enhancing capabilities and strengthening market position in specialty pharmaceuticals.
Raised fiscal 2026 guidance, projecting adjusted operating income growth of 11.5% to 13.5%.
Continued strength in U.S. healthcare solutions business, driven by a pharmaceutical-centric strategy and advanced analytics.
Significant advancements in clinical research and patient care through MSO expansion, positioning Cencora as a leader in the healthcare ecosystem.
Ongoing focus on enhancing patient access to innovative specialty medications and treatments through supportive operational frameworks.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit COR on AllInvestView.

Previous Q4 2025

Next Q2 2026